Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis

Introduction: Outcomes of immune checkpoint inhibitor (ICI) rechallenge in NSCLC remain uncertain. This study estimated the safety and efficacy of ICI rechallenge and compared rechallenge benefit among different reasons of initial ICI discontinuation in NSCLC. Methods: PubMed, EMBASE, and Cochrane L...

Full description

Bibliographic Details
Main Authors: Shiting Xu, MD, Takehito Shukuya, MD, PhD, Jun Tamura, MSc, Shoko Shimamura, MD, Kana Kurokawa, MD, Keita Miura, MD, Taichi Miyawaki, MD, PhD, Daisuke Hayakawa, MD, PhD, Tetsuhiko Asao, MD, PhD, Kouji Yamamoto, PhD, Kazuhisa Takahashi, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-04-01
Series:JTO Clinical and Research Reports
Subjects:
Immune checkpoint inhibitors
Non–small cell lung cancer
Rechallenge
Immune-related adverse events
Prognosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000339

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322000339

Similar Items